Why could gut microbiota become a medication?;Pourquoi la flore intestinale a-t-elle vocation à devenir médicament?

Annales Pharmaceutiques Francaises

Volumn 72, Issue 5, 2014, Pages 325-329

  Bourlioux, P ^a,b   Megerlin, F ^a,c   Corthier, G ^d   Gobert, J G ^a,c   Butel, M J ^c  

^a Laboratoire de Chimie Analytique et Electrochimie   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UMR1319 MICALIS   (France)

Author keywords

Flora transplantation; Gut microbiota; Medication; Symbiosis; Therapeutic

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; FECES MICROFLORA; HUMAN; INTESTINE FLORA; INTESTINE FLORA TRANSPLANTATION; MEDICAL RESEARCH; NONHUMAN; RISK FACTOR; TREATMENT INDICATION; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL TRACT; INTESTINE; MICROBIOLOGY;

FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; INTESTINES;

EID: 84922283892     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2014.03.005     Document Type: Short Survey

References (29)

1. Bourlioux P. Actualité du microbiote intestinal. Ann Pharm Fr 2014, 72:15-21.
2. Rosner J.L. Ten times more microbial cells than body cells in humans. Microbe 2014, 9:47.
3. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
4. Fox J.L. Microbiota studies generate data, excite speculation. Microbe 2013, 8:494-498.
5. Kulasooriya S.A. Cyanobacteria: pioneers of planet Earth. Ceylon J Sci 2011, 40:71-88.
6. Margulis L. Symbiotic theory of the origin of eukariotic organels. Criteria for proofs. Symp Soc Exp Biol 1975, 29:21-38.
7. Margulis L., Bermudes D. Symbiosis as a mechanism of evolution. Status of the cell symbiosis theory. Symbiosis 1985, 1:101-124.
8. Zilber-Rosenberg I., Rosenberg E. Role of microorganisms in the evolution of animals and plants: the hologenome theory of Evolution. FEMS Microbiol Rev 2008, 32:723-735.
9. Wilson D.S., Sober E. Reviving the superorganism. J Theor Biol 1989, 136:337-356.
10. Blaser M., Bork P., Fraser C., Knight R., Wang J. The microbiome explored: recent insights and future challenges. Nature Rev Microbiol 2013, 11:213-217.
11. Leonel A.J., Alvarez-Leite J.I. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012, 15:474-479.
12. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
13. Yu L.C., Wang J.T., Wei S.C., Ni Y.H. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol 2012, 3:27-43.
14. Collins S.M., Surette M., Bercik P. The interplay between the intestinal microbiota and the brain. Nature Rev Microbiol 2012, 10:735-742.
15. Franks I. Microbiota: gut microbes might promote intestinal angiogenesis. Nat Rev Gastroenterol Hepatol 2013, 10:3.
16. Pluznick J.L., Protzko R.J., Gevorgyan H., Peterlin Z., Sipos A., Han J., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013, 110:4410-4415.
17. Bassler B.L., Losick R. Bacterially speaking. Cell 2006, 125:237-246.
18. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
19. Eaton S.R., Mazuski J.E. Overview of severe Clostridium difficile infection. Crit Care Clin 2013, 29:827-839.
20. Waligora-Dupriet A.J., Butel M.J. Microbiota and allergy: from dysbiosis to probiotics. Allergic diseases-Highlights in the clinic, mechanisms and treatment 2012, 413-414. Intech, Rijeka. C. Pereira (Ed.).
21. Kamada N., Seo S.U., Grace Y., Chen G.Y., Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013, 13:321-336.
22. DiBaise J.K., Zhang H., Crowell M.D., Krajmalnik-Brown R., Decker G.A., Rittmann B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008, 83:460-469.
23. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
24. Finegold S.M. State of the art: microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 2011, 17:367-368.
25. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
26. Borody T.J., Brandt L.J., Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014, 30:97-105.
27. Hyde M.J., Mostyn A., Modi N., Kemp P.R. The health implications of birth by Caesarean section. Biol Rev 2012, 87:229-243.
28. Huh S.Y., Rifas-Shiman S.L., Zera C.A., Edwards J.W., Oken E., Weiss S.T., et al. Delivery by caesarean section and risk of obesity in preschool age children: a prospective cohort study. Arch Dis Child 2012, 97:610-616.
29. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.